ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1703 National Cancer Institute Html en Tumor Grade A fact sheet that discusses tumor grade and its role in prognosis. Explains concepts like normal cell biology and cell differentiation.
Gleason score0.401724
NCI fact sheet0.404685
lower grade0.405507
tissue organization0.400496
better prognosis0.354968
tumor tissue0.703634
type-specific grading systems0.412132
tumor type0.491464
cancer cells0.405656
biopsied tissue0.413701
Gleason scores0.355221
primary brain tumors0.42294
tumor size0.501863
abnormal-looking cells0.400459
Nottingham grading0.360235
higher-grade cancer0.364598
tumor cells0.631844
normal cells0.49423
nearby lymph nodes0.408457
tumor grade0.785451
regional lymph node0.409603
secondary pattern0.388809
breast tumors0.384185
Scarff-Bloom-Richardson grading0.361738
normal tissue structures0.487646
primary pattern0.353415
microscopic examination0.353649
breast cancer0.39308
biopsy samples0.354483
Staging page0.357155
microscopic appearance0.359178
different types0.358151
tumors0.490957
prostate cancer0.440387
cancer staging0.368981
slower rate0.360886
American Joint Committee0.39399
tumor0.981653
tumor grades0.501473
common tissue pattern0.44497
cancer0.557882
total score0.354108
soft tissue sarcoma0.443518
prostate cancers0.367392
Gleason scoring0.35738
tumor tissue look0.635152
cancer stage0.457333
CLICK HERE
1806 National Cancer Institute Html es Tratamiento del cáncer de estómago (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del cáncer de estómago.
after d2 gastrectomy0.313513
gastrectomía d20.31496
Cunningham D0.34388
Macdonald JS0.318723
Chemoradiotherapy after surgery0.344328
randomised controlled0.319618
combined modality therapy0.360634
mejoría significativa0.31176
Stenning SP0.310838
intergroup trial calgb0.31542
Postoperative adjuvant chemoradiation0.322032
after ci 5-fu0.317294
fase iii0.364462
Estados Unidos0.347269
with s-10.314235
randomized trial comparing0.314288
quimiorradioterapia posoperatoria0.360835
ensayo rtog-99040.324678
patients with0.484752
adyuvante versus tasa0.360686
supportive care0.325372
Clinical Oncology0.311085
Perioperative chemotherapy versus0.334581
chemotherapy plus best0.312401
Smalley SR0.318682
with surgery0.339493
Ajani JA0.354002
or gastroesophageal junction0.340588
ensayo swog-s04250.324881
Allum WH0.311046
quimiorradioterapia adyuvante versus0.364135
estadio ib0.338006
gastrectomía curativa d20.319296
Van Cutsem E0.313883
Benedetti J0.318647
quimioterapia perioperatoria0.352185
gastric carcinoma0.325701
gastric cancer0.935626
Clin Oncol0.612714
or gastro-oesophageal junction0.317111
trial comparing0.314461
supportive care with0.324232
Winter K0.319459
Gastric Cancer Study0.317632
chemotherapy versus surgery0.338116
grupo s-10.317965
Okawara GS0.319919
care with best0.314996
quimioterapia posoperatoria0.31518
CLICK HERE
1871 National Cancer Institute Html es Tratamiento del carcinoma de sitio primario desconocido (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del carcinoma de sitio primario desconocido.
cáncer epitelial versus0.404134
Greco FA0.432795
unknown primary tumours0.414817
cisplatin-based combination chemotherapy0.404363
unknown primary site0.721557
Pavlidis N0.405224
Breast carcinoma presenting0.411406
unknown primary origin0.450607
Hainsworth JD0.442528
Metastatic malignant melanoma0.405856
Cancer Res0.404192
Radiat Oncol Biol0.414855
neuroendocrine carcinoma0.415368
Natl Cancer Inst0.417117
poorly differentiated0.438667
Melanoma from unknown0.410685
serous papillary carcinoma0.405287
patients with0.456873
gene expression profiling0.404698
unknown primary carcinoma0.451216
carcinoma nasofaríngeo0.409399
poorly differentiated carcinoma0.41977
cervical lymph0.404293
patients with unknown0.4336
Rodriguez E0.405003
presenting as axillary0.404521
metastases from unknown0.428245
Unknown primary melanoma0.416245
Abbruzzese MC0.404845
Curr Probl Cancer0.404442
primary neoplasm0.406005
or undiscovered primary0.406863
from unknown primary0.455678
primary tumor site0.417993
Surg Oncol0.405079
PDQ Tratamiento0.416061
Intern Med0.413673
nasopharyngeal carcinoma0.405469
Clin Oncol0.44391
Johnson DH0.404766
unknown primary0.993061
Oncol Biol Phys0.415244
with unknown primary0.46599
metastatic adenocarcinomas0.408539
unknown primary tumor0.442645
germ cell tumors0.405207
carcinoma presenting as0.411228
occult primary carcinoma0.410287
cancer incidence0.406991
CLICK HERE
1875 National Cancer Institute Html es Tratamiento del linfoma relacionado con el sida (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del linfoma relacionado con el sida.
aids-related non-hodgkin lymphomas0.608138
non-hodgkin's lymphomas0.666621
prognostic factors0.350902
HIV-associated Hodgkin0.399104
Spina M0.351065
linfoma hodgkin0.348723
Epstein-Barr virus0.393918
atypical burkitt lymphoma0.351153
large b-cell lymphoma0.344814
HIV-related lymphoma0.343107
immunodeficiency virus0.402901
highly active0.512378
human immunodeficiency virus-associated0.403779
Burkitt lymphoma0.387609
immunodeficiency virus-associated non-Hodgkin0.342734
AIDS patients with0.376046
Dunleavy K0.344239
Natl Cancer Inst0.464946
active antiretroviral therapy0.726916
central nervous system0.649203
human immunodeficiency virus-related0.374511
HIV-infected patients with0.343338
immunodeficiency syndrome-related lymphoma0.354213
lymphoma treated with0.43581
patients with0.924942
patients with primary0.375652
chemotherapy with0.357715
human immunodeficiency0.754154
patients with aids-related0.424038
oral t-cell lymphoma0.346331
acquired immunodeficiency syndrome-related0.357324
lymphoma is dramatically0.348699
immunodeficiency virus-related lymphoma0.359105
acquired immunodeficiency0.378848
aids-related lymphoma0.736141
treatment with0.389583
primary central nervous0.521797
Intern Med0.353617
Clin Oncol0.792214
sistema nervioso central0.421872
systemic aids-related non-hodgkin0.367456
non-hodgkin lymphoma0.744829
Hodgkin lymphoma treated0.362251
study with0.356196
hiv-associated lymphomas0.544837
primary effusion lymphoma0.456053
nervous system lymphoma0.736571
células b0.35592
AIDS-related primary lymphoma0.361221
CLICK HERE
1943 National Cancer Institute Html es Síndromes cardiopulmonares (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca de las afecciones comunes que producen síntomas en el tórax. Los síndromes cardiopulmonares que se exponen en este sumario son la disnea relacionada con el cáncer, el derrame pleural maligno, el derrame pericárdico y el síndrome de la vena cava superior.
pleural catheter0.17861
Ripamonti C0.130559
dificultad respiratoria0.26023
malignant effusion0.115362
lung cancer0.190962
Sin embargo0.114284
end-of-life patients with0.119385
indwelling pleural catheter0.162022
Dudgeon DJ0.13043
fármacos pleurales esclerosantes0.112004
disfunción muscular respiratoria0.121219
Hematol Oncol Clin0.143013
hypoxemic patients with0.118489
patients receiving chemotherapy0.111162
Cancer Organisation Thoracic0.117844
antitusivos opioides0.112496
recurrent symptomatic malignant0.110714
patients with0.625852
insuficiencia cardiaca0.134239
Pain Symptom Manage0.478956
randomized controlled0.112081
pleural fluid0.136904
Cancer Dyspnea Scale0.146703
Moroni M0.110841
Care Cancer0.128094
pleural catheter vs0.135869
Physiol Neurobiol0.116436
as symptomatic treatment0.110943
derrame maligno fracasa0.114534
obstructiva crónica0.135859
vías respiratorias0.205286
tunnelled pleural catheter0.139919
tos crónica causa0.111919
prospective randomized0.110614
pleural effusions with0.149859
Intern Med0.132242
Clin Oncol0.11762
Med Pediatr Oncol0.111608
Clin North Am0.136363
Bruera E0.203018
systematic review0.116364
Oncol Clin North0.140711
American Thoracic Society0.114142
as palliative treatment0.110799
malignant pleural effusions0.900896
Crit Care Med0.171232
symptomatic malignant0.122652
alone versus0.11566
compared with0.110951
CLICK HERE
2082 National Cancer Institute Html en Cancer Clusters A fact sheet that describes what constitutes a cancer cluster and the process for reporting and investigating suspected clusters.
major risk factor0.385962
specific environmental hazards0.38074
rare cancer0.409989
website uses data0.380594
cancer trends0.398646
individual cancer clusters0.469731
number0.405815
investigators0.393508
Health Hazard Evaluation0.380995
Disease Control0.519415
Health Consultations page0.381331
cancer cluster0.895701
cancer clusters0.841764
National Center0.381056
ATSDR regional offices0.380684
different geographic area0.38274
cluster investigations0.411002
true cancer clusters0.482566
public health assessments0.472612
statistically significant difference0.384068
vinyl chloride0.380035
specific cancer type0.434002
primary cancer0.413707
U.S. Census Bureau0.37492
specific hazardous substances0.37613
different cancer types0.429181
state health department0.450442
total number0.385248
cancer cases0.749447
health departments0.457783
NCI analyze variations0.380726
local health departments0.450682
geographic area0.518161
specific geographic area0.389344
health surveillance programs0.382617
people0.378106
epidemiologic study0.378396
agency gathers information0.381997
statistically significant excess0.455543
secondary cancer0.393665
cancer0.954313
state cancer registries0.443891
cancer cluster—that0.391887
Disease Registry0.381886
specific time period0.392616
Toxic Substances0.380998
cancer death rates0.436653
cancer incidence0.401099
Cancer Mortality Maps0.435229
CLICK HERE
3564 National Cancer Institute Html en The NCI Intramural Research Program The intramural research program supports projects conducted by scientists located at NCI.
intramural cancer research0.718907
intramural research program0.874728
public health issues0.586317
IRP researchers0.99482
clinical disciplines0.535611
basic research discovery0.633697
cancer initiation0.556039
NCI offices0.598153
private sector partners0.575197
long-term cohort studies0.573663
NCI intramural research0.823709
extramural institutions0.555913
future research0.545095
clinical trials0.610273
sophisticated statistical approaches0.591904
outstanding scientific credentials0.582191
rare cancers0.616347
outstanding research0.546529
clinical IRP researchers0.677303
extramural investigators0.808101
basic scientific research0.670523
cervical cancer0.590079
traditional funding mechanisms0.574359
Early-stage clinical trials0.595705
intramural researchers0.664665
Cancer Epidemiology0.564756
population-based research0.591379
various reasons—to fund0.579705
National Cancer Program0.628399
cancer prevention0.546859
noninfectious virus-like particles0.5887
relatively little funding0.573973
cancer research0.783668
academic institutions0.606037
high-reward research0.541951
NCI IRP0.623146
CCR’s John0.543838
NIH Clinical Center0.948229
public health needs0.603453
Intramural research projects0.689496
research program complement0.627977
basic cancer research0.675487
research resources0.556851
CCR researcher Ira0.613887
NCI components0.59726
CCR colleagues0.538611
cancer risk0.53862
federal government investigators0.655439
CLICK HERE
3569 National Cancer Institute Html en Lung-MAP: Master Protocol for Squamous Cell Lung Cancer A collection of material about the Lung-MAP study, which will examine treatment outcomes for patients with squamous cell lung cancer assigned to different targeted drugs based on the results of genomic tumor profiling.
Cancer Master Protocol0.761779
cancer-related genes0.485085
similar large cancer0.550307
unique public-private collaboration0.635287
biomarker-driven clinical trial0.547514
genomic screening0.486006
immune system fight0.473995
lung cancer0.958963
Cancer Therapy Evaluation0.548913
National Clinical Trials0.624831
genomic profile0.494996
clinical testing0.479299
U.S. Food0.476247
advanced squamous cell0.974568
Squamous cell carcinoma0.611382
drug nivolumab0.477374
typical clinical trial0.556218
patients0.598987
new investigational treatment0.557707
single biomarker0.478327
standard approach0.479591
current standard0.486778
drug developers0.47659
screening tests0.477882
Drug Administration0.477451
cancer cells0.493264
phase II/III trial0.55125
squamous cell lung0.99877
Clinical Trials Network0.627666
precision medicine trial0.62764
website provides information0.530495
Cancer Research0.488908
treatment arm0.481046
Lung Cancer Master0.790983
different experimental treatments0.535025
genomic profiling0.496642
targeted therapy tests0.532918
genomic alterations0.502152
genetic alteration0.474138
trial arm0.505132
investigational treatments0.488936
genetic changes0.47769
Lung-MAP Launches0.474509
cell lung cancer0.935701
treatment options0.487036
greater likelihood0.474643
biologics R&D arm0.540299
new targeted therapies0.528849
CLICK HERE
17172 National Cancer Institute Html es Hongos medicinales (PDQ®)–Versión para pacientes Resumen de información revisada por expertos sobre el uso de los hongos medicinales como tratamiento para las personas con cáncer.
tumores colorrectales benignos0.523017
Centro Nacional0.437112
New Hampshire Avenue0.425865
Coriolus versicolor0.603005
Drug Administration0.41603
NCI Best Case0.44366
hongo tejado0.42735
hongos trametes0.464694
tipo ganoderma0.427842
datos bibliográficos pubmed0.427701
siguientes preguntas0.418216
células t0.427868
hongos cola0.470178
siguientes riesgos0.422485
Instituto Nacional0.543935
Ganoderma lucidum0.60047
Salud Complementaria0.454998
Visuals Online0.419017
sumario hongos0.465605
polisacárido -K0.427899
complementarias revisa0.427138
Physician Data Query0.509146
Estados Unidos0.759861
estadio iii0.424138
libre uso0.423898
Lentinus edodes0.430494
Asia Oriental0.421328
página manejo0.417832
¿El tratamiento0.429283
inmunitarias llamadas linfocitos0.447603
¿Los beneficios0.416234
juntos cam0.415492
Series Program0.416063
medicina complementaria0.932021
Trametes versicolor0.613189
tipo cola0.441661
CLICK HERE
17279 National Cancer Institute Html es Planes para atender un cáncer avanzado Una planificación cuidadosa reducirá el peso que enfrentará su familia más adelante. La planificación puede incluir aspectos económicos y legales, pero como verá, también puede ser una forma de celebrar su vida y de darle significado.
tensiones. Algunas personas0.876955
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.